
- /
- Supported exchanges
- / US
- / PHIO.NASDAQ
Phio Pharmaceuticals Corp (PHIO NASDAQ) stock market data APIs
Phio Pharmaceuticals Corp Financial Data Overview
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Phio Pharmaceuticals Corp data using free add-ons & libraries
Get Phio Pharmaceuticals Corp Fundamental Data
Phio Pharmaceuticals Corp Fundamental data includes:
- Net Revenue:
- EBITDA: -7 048 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Phio Pharmaceuticals Corp News

Phio Pharma stock maintains buy rating as cancer trial advances
Investing.com - H.C. Wainwright has reiterated its buy rating and $14.00 price target on Phio Pharma (NASDAQ:PHIO), representing significant upside from the current price of $2.17. According to Invest...


Phio's PH-762 shows positive safety profile in fourth cohort trial
MARLBOROUGH, MASSACHUSETTS - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a $10.6 million market cap biotechnology company whose stock has gained over 22% year-to-date, announced Wednesday that its Safet...

Best Value Stocks to Buy for May 28th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, May 28th: Phio Pharmaceuticals PHIO: This company which is focused on developing immuno-oncology ...

Best Momentum Stocks to Buy for April 23rd
Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, April 23: Casella Waste Systems, Inc. CWST: This integrated solid waste services company has a Z...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.